SEC Form 4 · accession 0001209191-16-140825
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry J. Simon
Officer — President and COO · Director
Period of report
Sep 7, 2016
Accepted (ET)
Sep 9, 2016 · 6:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 7, 2016 | S | 2,000 | $8.8356 | D | 21,143 | I | By mother-in-law |
| Common Stock | Sep 8, 2016 | S | 30,000 | $7.40 | D | 3,334,906 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $60.00 to $60.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.